Identifying the proteins to which small-molecule probes and drugs bind in cells

Most small-molecule probes and drugs alter cell circuitry by interacting with 1 or more proteins. A complete understanding of the interacting proteins and their associated protein complexes, whether the compounds are discovered by cell-based phenotypic or target-based screens, is extremely rare. Such a capability is expected to be highly illuminating—providing strong clues to the mechanisms used by small-molecules to achieve their recognized actions and suggesting potential unrecognized actions. We describe a powerful method combining quantitative proteomics (SILAC) with affinity enrichment to provide unbiased, robust and comprehensive identification of the proteins that bind to small-molecule probes and drugs. The method is scalable and general, requiring little optimization across different compound classes, and has already had a transformative effect on our studies of small-molecule probes. Here, we describe in full detail the application of the method to identify targets of kinase inhibitors and immunophilin binders.

[1]  M. Mann,et al.  Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. , 2008, Molecular cell.

[2]  R. Higgs,et al.  An immuno-chemo-proteomics method for drug target deconvolution. , 2008, Journal of proteome research.

[3]  B. Cravatt,et al.  Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. , 2008, Annual review of biochemistry.

[4]  Wen-Chien Lee,et al.  Chromatographic characterization of molecularly imprinted polymers , 2008, Analytical and bioanalytical chemistry.

[5]  S. Schreiber,et al.  Small-molecule reagents for cellular pull-down experiments. , 2008, Bioconjugate chemistry.

[6]  G. Terstappen,et al.  Target deconvolution strategies in drug discovery , 2007, Nature Reviews Drug Discovery.

[7]  A. Tanaka.  [A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[8]  Bernhard Kuster,et al.  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.

[9]  Anne E Carpenter.  Image-based chemical screening. , 2007, Nature chemical biology.

[10]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[11]  G. Fischer,et al.  Solution Structure of the FK506-Binding Domain of Human FKBP38 , 2006, Journal of biomolecular NMR.

[12]  Lin Tang,et al.  Roscovitine Targets, Protein Kinases and Pyridoxal Kinase*[boxs] , 2005, Journal of Biological Chemistry.

[13]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[14]  Stuart L Schreiber,et al.  Using genome-wide transcriptional profiling to elucidate small-molecule mechanism. , 2005, Current opinion in chemical biology.

[15]  B. Stockwell.  Exploring biology with small organic molecules , 2004, Nature.

[16]  D. Brehmer,et al.  Proteome-wide Identification of Cellular Targets Affected by Bisindolylmaleimide-type Protein Kinase C Inhibitors* , 2004, Molecular & Cellular Proteomics.

[17]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[18]  S. Schreiber,et al.  A planning strategy for diversity-oriented synthesis. , 2004, Angewandte Chemie.

[19]  Todd R Golub,et al.  Gene expression–based high-throughput screening(GE-HTS) and application to leukemia differentiation , 2004, Nature Genetics.

[20]  M. Cotten,et al.  An efficient proteomics method to identify the cellular targets of protein kinase inhibitors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Strausberg,et al.  From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule Probes , 2003, Science.

[22]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[23]  Blagoy Blagoev,et al.  A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling , 2003, Nature Biotechnology.

[24]  M. Mann,et al.  Properties of 13C-substituted arginine in stable isotope labeling by amino acids in cell culture (SILAC). , 2003, Journal of proteome research.

[25]  Ruedi Aebersold,et al.  The study of macromolecular complexes by quantitative proteomics , 2003, Nature Genetics.

[26]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[27]  M. Mann,et al.  Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics* , 2002, Molecular & Cellular Proteomics.

[28]  B. Cravatt,et al.  Activity-based protein profiling: the serine hydrolases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Holt,et al.  Synthesis and activity of bivalent FKBP12 ligands for the regulated dimerization of proteins. , 1998, Bioorganic & medicinal chemistry.

[30]  L. Havlícek,et al.  Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.

[31]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[32]  J. Lippke,et al.  Expression and characterization of human FKBP52, an immunophilin that associates with the 90-kDa heat shock protein and is a component of steroid receptor complexes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S. Schreiber,et al.  A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase , 1989, Nature.

[34]  S. Nakanishi,et al.  The effect of K-252a, a potent microbial inhibitor of protein kinase, on activated cyclic nucleotide phosphodiesterase. , 1988, The Biochemical journal.

[35]  C. Anfinsen,et al.  Selective enzyme purification by affinity chromatography. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Lindsay.  Target discovery , 2003, Nature Reviews Drug Discovery.